Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Diagnostics (Basel) ; 10(2)2020 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-32024166

RESUMO

BACKGROUND: The high burden of disease in South Africa presents challenges to public health services. Point-of-care (POC) technologies have the potential to address these gaps and improve healthcare systems. This study ascertained the acceptability and impact of POC CD4 testing on patients' health and clinical management. METHODS: We conducted a qualitative survey study with patients (n = 642) and healthcare providers (n = 13) at the Lancers Road (experienced POC) and Chesterville (non-experienced POC) primary healthcare (PHC) clinics from September 2015 to June 2016. RESULTS: Patients (99%) at Lancers and Chesterville PHCs were positive about POC CD4 testing, identifying benefits: No loss/delay of test results (6.4%), cost/time saving (19.5%), and no anxiety (5.1%), and 58.2% were ready to initiate treatment. Significantly more patients at Chesterville than Lancers Road PHC felt POC would provide rapid clinical decision making (64.7% vs. 48.1%; p < 0.0001) and better clinic accessibility (40.4% vs. 24.7%; p < 0.0001) respectively. Healthcare providers thought same-day CD4 results would impact: Clinical management (46.2%), patient readiness (46.2%), and adherence (23.0%), and would reduce follow-up visits (7.7%), while 38.5% were concerned that further tests and training (15.4%) were required before antiretroviral therapy (ART) initiation. CONCLUSION: The high acceptability of POC CD4 testing and the immediate health, structural, and clinical management benefits necessitates POC implementation studies.

2.
Spat Spatiotemporal Epidemiol ; 30: 100283, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-31421797

RESUMO

OBJECTIVE: We identified the geographical clustering of HIV as well as those at highest risk of infection using a decade long data (2002-2012) from KwaZulu-Natal, South Africa. METHODS: A total of 5,776 women who enrolled in several HIV prevention trials were included in the study. Geo-coded individual-level data were linked to the community-level characteristics using the South African Census. High-risk women were identified using a risk scoring algorithm. Generalized additive models were used to identify the significant geographical clustering of high-risk women and HIV. RESULTS: Overall, 60% of the women were classified as high risk of HIV. HIV infection rates were estimated as high as 10 to 15 per 100 person year. Areas with high rates of HIV infections were spatially clustered and overlapped particularly in the Northern part of Durban. CONCLUSION: Targeting multifactorial and complex nature of the epidemic is urgently needed to identify the "high transmission" areas.


Assuntos
Atenção à Saúde/organização & administração , Infecções por HIV , Necessidades e Demandas de Serviços de Saúde , Saúde da Mulher , Adulto , Análise por Conglomerados , Feminino , Infecções por HIV/epidemiologia , Infecções por HIV/prevenção & controle , Infecções por HIV/transmissão , Humanos , Prevalência , Medição de Risco/métodos , Fatores de Risco , África do Sul/epidemiologia
3.
Dev World Bioeth ; 13(2): 87-94, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23725227

RESUMO

The successful demonstration that antiretroviral (ARV) drugs can be used in diverse ways to reduce HIV acquisition or transmission risks--either taken as pre-exposure prophylaxis (PrEP) by those who are uninfected or as early treatment for prevention (T4P) by those living with HIV--expands the armamentarium of existing HIV prevention tools. These findings have implications for the design of future HIV prevention research trials. With the advent of multiple effective HIV prevention tools, discussions about the ethics and the feasibility of future HIV prevention trial designs have intensified. This article outlines arguments concerning the inclusion of newly established ARV-based HIV prevention interventions as standard of prevention in HIV prevention trials from multiple perspectives. Ultimately, there is a clear need to incorporate stakeholders in a robust discussion to determine the appropriate trial design for each study population.


Assuntos
Fármacos Anti-HIV/administração & dosagem , Ensaios Clínicos como Assunto/ética , Ensaios Clínicos como Assunto/normas , Pesquisa Participativa Baseada na Comunidade/ética , Infecções por HIV/prevenção & controle , Prevenção Primária/ética , Adenina/administração & dosagem , Adenina/análogos & derivados , Pesquisa Participativa Baseada na Comunidade/normas , Pesquisa Participativa Baseada na Comunidade/tendências , Desoxicitidina/administração & dosagem , Desoxicitidina/análogos & derivados , Quimioterapia Combinada , Emtricitabina , Ética em Pesquisa , Necessidades e Demandas de Serviços de Saúde , Humanos , Organofosfonatos/administração & dosagem , Guias de Prática Clínica como Assunto , Prevenção Primária/métodos , Projetos de Pesquisa , Tenofovir , Falha de Tratamento , Estados Unidos , United States Food and Drug Administration
4.
Sex Transm Dis ; 39(7): 567-75, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22706221

RESUMO

BACKGROUND: This study aimed to document the clinical practices and attitudes of health care providers in South Africa and Zimbabwe on male circumcision for human immunodeficiency virus (HIV) prevention. METHODS: We conducted national surveys of physicians and nurses in both countries in 2008-2009 (N = 1444). Data on male circumcision for HIV prevention were analyzed; outcomes were patient counseling, provision of services, and desire for training. We used multivariable logistic regression to examine associations between these outcomes and clinician, practice, and attitudinal variables. RESULTS: Overall, 57% of clinicians reported counseling male patients on male circumcision, 17% were offering services (49% referrals), and 61% desired training. In the multivariable analyses, provision of services was more common in South Africa (P ≤ 0.001) but desire for training higher in Zimbabwe (P ≤ 0.01). Provision of services was highest among physicians (P ≤ 0.01) and in hospital settings (P ≤ 0.001). However, nurses had greater desire for training (P ≤ 0.05) as did younger clinicians (P ≤ 0.001). Clinicians in rural and clinic settings were just as likely to express training interest. Clinician attitudes that patients would be upset due to cultural beliefs and would increase risky behaviors were associated with less counseling and service provision (P ≤ 0.05). CONCLUSIONS: Many clinicians in South Africa and Zimbabwe showed willingness to integrate new HIV prevention evidence into practice and to become trained to offer the procedure to patients. Results suggest that both countries should consider involving nurses in male circumcision for HIV prevention, including those in rural areas, and should help clinicians to address cultural concerns.


Assuntos
Síndrome da Imunodeficiência Adquirida/prevenção & controle , Circuncisão Masculina/métodos , Atenção à Saúde/métodos , Enfermeiras e Enfermeiros/estatística & dados numéricos , Médicos/estatística & dados numéricos , Padrões de Prática Médica , Síndrome da Imunodeficiência Adquirida/epidemiologia , Adulto , Circuncisão Masculina/estatística & dados numéricos , Aconselhamento/organização & administração , Características Culturais , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Masculino , Fatores de Risco , Assunção de Riscos , África do Sul/epidemiologia , Inquéritos e Questionários , Zimbábue/epidemiologia
5.
AIDS Behav ; 15(2): 479-86, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20981479

RESUMO

The objective of this study was to estimate the joint impact of demographic and sexual risk behaviors on HIV acquisition. A total of 2,523 HIV seronegative women were recruited through three community based studies in Durban, South Africa. Point and interval estimates of partial population attributable risk (PAR) were used to quantify the proportion of HIV seroconversions which can be prevented if a combination of risk factors is eliminated from a target population. More than 80% of the observed HIV acquisitions were attributed to five risk factors: lack of cohabitation, frequency of sex, sexually transmitted infections (STIs), incidence of pregnancy and not being employed/no income. Structural factors such as minimizing migratory patterns by ensuring cohabitation of partners, access to treatment of STIs, income generation and safe sex negotiation skills are likely to play an important role in future prevention strategies.


Assuntos
Infecções por HIV/epidemiologia , Infecções por HIV/prevenção & controle , Soropositividade para HIV/epidemiologia , Assunção de Riscos , Infecções Sexualmente Transmissíveis/prevenção & controle , Adulto , Fatores Etários , Feminino , Seguimentos , Infecções por HIV/diagnóstico , Soropositividade para HIV/diagnóstico , Política de Saúde , Humanos , Incidência , Gravidez , Fatores de Risco , Comportamento Sexual , Parceiros Sexuais , Infecções Sexualmente Transmissíveis/diagnóstico , Infecções Sexualmente Transmissíveis/epidemiologia , Fatores Socioeconômicos , África do Sul/epidemiologia , Inquéritos e Questionários , Adulto Jovem
6.
BMC Med Ethics ; 10: 16, 2009 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-19788765

RESUMO

BACKGROUND: A recent paper presents an argument and mechanism for the possible stopping of clinical trials early based on opportunity costs. DISCUSSION: Although we agree that the costs and opportunity costs of clinical trials need to be reduced wherever possible, we raise concerns about the motivation and mechanism for stopping clinical trials early raised by Lavery et al. SUMMARY: We argue that there are already enough acceptable criteria and actors in the clinical trials arena to justify early stoppage of clinical trials, and argue that factors other than efficacy need to be carefully considered, especially in developing country contexts.


Assuntos
Anti-Infecciosos/economia , Anti-Infecciosos/uso terapêutico , Ensaios Clínicos como Assunto/economia , Países em Desenvolvimento , Fármacos Anti-HIV/economia , Fármacos Anti-HIV/uso terapêutico , Ensaios Clínicos Fase III como Assunto/economia , Países em Desenvolvimento/economia , Saúde Global , Infecções por HIV/prevenção & controle , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto/economia , África do Sul
7.
J Infect Dis ; 196 Suppl 3: S523-7, 2007 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-18181705

RESUMO

From 2003 to 2006, the number of human immunodeficiency virus-infected people in sub-Saharan Africa able to access antiretroviral therapy (ART) has increased from 100,000 to >1 million. The World Health Organization estimates that >3.5 million patients are still in need. The challenges to more expeditious provision of ART in Africa are many. This article is an analysis of the barriers to ART scale-up that are unique to South Africa. With 5.3 million people infected and 1 million needing ART, this country carries nearly one-quarter of the treatment burden of the continent. Although South Africa is undeniably a middle-income nation, inequities born of apartheid, lack of political commitment, poverty, and cultural barriers have significantly slowed efforts to provide universal access to ART to South African citizens.


Assuntos
Terapia Antirretroviral de Alta Atividade/métodos , Infecções por HIV/tratamento farmacológico , Acessibilidade aos Serviços de Saúde , Infecções por HIV/economia , Infecções por HIV/epidemiologia , Infecções por HIV/virologia , Humanos , África do Sul/epidemiologia , Organização Mundial da Saúde
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA